The project involves a multidisciplinary collaboration between Dr. Martinez-Moreno, Dr. Sullivan’s lab, and other research groups at institutions such as the University of Rhode Island (URI). These partnerships focus on optimizing hydrogel compositions and advancing therapeutic applications.

The study seeks to apply hydrogels for sustained drug release in chordoma, an area that has not been previously explored. It also investigates epigenetic restriction therapeutics and immunotherapies in preclinical models using both immunocompromised and humanized mice.

This work has significant translational potential, bridging fundamental research and clinical application. It could contribute to novel, non-invasive therapeutic strategies for chordoma and lead to publications in both basic and clinical research journals.